← Eichor
Condition: Translocation Renal Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Translocation Renal Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Phase 2 · 2 location(s) · Stephanie Berg · NCT07123090A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1/Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06835972Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05665361
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.